«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2015年第2期

页码:

155-160

栏目:

临床研究

出版日期:

2014-10-25

文章信息/Info

Title:

Intracoronary bolus plus intravenous half-dose maintenance administration of tirofiban in elderly patients undergoing primary percutaneous coronary intervention for acute myocardial infarction

作者:

何 芸; 赵 强; 王淑香; 徐元杰; 罗景云; 黄伟光; 吴同果

(广州市红十字会医院、暨南大学医学院第四附属医院心内科，广东 广州 510220)

Author(s):

HE Yun;  ZHAO Qiang;  WANG Shu-xiang;  XU Yuan-jie;  LUO Jing-yun;  HUANG Wei-guang;  WU Tong-guo

(Department of Cardiology, Guangzhou Red Cross Hospital & Fourth Affiliated Hospital of Jinan University, Guangzhou 510220, Guangdong, China)

关键词:

心肌梗死; 急性; 经皮冠状动脉介入治疗; 替罗非班; 老年

Keywords:

acute myocardial infarction;  percutaneous coronary angioplasty;  tirofiban;  aged

分类号:

R542.22

DOI:

-

文献标识码:

A

摘要:

目的:探讨因急性心肌梗死(AMI)行急诊经皮冠状动脉(冠脉)介入治疗(PCI)的老年患者，冠脉内(IC)联合静脉内应用半剂量替罗非班的有效性及安全性。方法:年龄≥70岁、因AMI行急诊PCI的患者104例，被随机分为常规剂量组（52例）和半剂量组（52列）。两组均IC替罗非班负荷剂量10 μg/kg，常规组和半剂量组分别以0.15、0.075 μg/(kg·min)持续静脉泵入24 h。比较两组PCI术后心电图ST段完全回落率(STEMI患者)，血清高敏肌钙蛋白T(hs-cTnT)峰值，梗死相关动脉(IRA)血栓积分、TIMI血流分级, TIMI心肌灌注分级(TMPG)；二磷酸腺苷(ADP)、花生四烯酸(AA)和胶原(COL)3种诱导剂作用下的血小板聚集程度(全血电阻抗法, WBIA)；PCI术后90 d左心室射血分数(LVEF)及主要不良心血管事件(MACEs)发生率的差异。比较两组用药期间出血及血小板减少发生率的差异。结果:半剂量组PCI术后ST段完全回落率(84% vs. 86%)、血清hs-cTnT峰值〔(5.1±1.9) μg/L vs.(5.8±2.6) μg/L〕，PCI术后即刻血栓积分〔(1.0±0.5)分 vs.(1.1±0.6)分〕、TIMI Ⅲ级血流(86% vs. 88%)和TMPG Ⅲ级(78% vs. 80%)获得率方面和常规剂量组比较均无统计学差异。半剂量组ADP〔(0.4±0.8) Ohms vs.(0.2±0.7)〕 Ohms)、AA〔(0.10±0.36) Ohms vs.(0.06±0.24) Ohms〕、COL〔(11±5) Ohms vs.(9±5) Ohms〕3种诱导剂诱导的血小板聚集程度与常规剂量组比较均无统计学差异。半剂量组患者PCI术后90 d的LVEF(57±6 vs. 58±68)、总MACEs的发生率和常规剂量组比较无显著差异。半剂量组总出血事件的发生率显著低于常规剂量组(P<0.05)。两组血小板减少的发生率比较无显著差异。结论:对于行急诊PCI的老年AMI患者，在IC负荷剂量的基础上，静脉内半剂量与常规剂量替罗非班相比较无显著差异，但可以更好地降低出血事件的发生。

Abstract:

AIM:To investigate the efficacy and safety of intracoronary (IC) bolus plus intravenous (IV) half-dose maintenance administration of tirofiban in aged patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). METHODS: One hundred and four patients aged 70 years and above undergoing primary PCI for AMI were divided into control group (n=52) and study group (n=52). Tirofiban was administered as an intracoronary bolus injection (10 μg/kg) in all patients followed by maintenance IV infusion at 0.15 μg/(kg·min) in control group and at 0.075 μg/(kg·min) in study group for 24 h. Complete ST-segment resolution (STR) in STEMI patients, peak concentration of serum high-sensitive cardiac troponin T (hs-cTnT), scores of thrombus, TIMI flow grade in the infarct-related artery (IRA) and TMI myocardial perfusion grade (TMPG) were analyzed in the two groups. Platelet aggregation in response to adenosine diphosphate (ADP), arachidonic acid (AA) or collagen (COL) was measured with whole blood impedance aggregometry (WBIA) 4 h after tirofiban initiation. Left ventricular ejection fraction (LVEF) and major adverse cardiovascular events (MACEs) were assessed 90 days following PCI. The rates of bleeding and thrombocytopenia were assessed during tirofiban administration. RESULTS: The percentage of patients with complete STR (84% vs. 86%), peak hs-cTnT level ［(5.1±1.9) μg/L vs.(5.8±2.6) μg/L］, scores of thrombus in the IRA (1.0±0.5 vs. 1.1±0.6), the percentage of patients with TIMI flow score of III (86% vs. 88%) and TMPG III (78% vs. 80%) postintervention did not differ significantly between study group and control group. Study group was similar with control group in terms of platelet aggregation in response to ADP ADP ［(0.4±0.8) Ohms vs.(0.2±0.7) Ohms］, AA ［(0.10±0.36) Ohms vs.(0.06±0.24) Ohms］, COL［(11±5) Ohms vs.(9±5) Ohms］. No significant differences were observed between groups in LVEF (57±6 vs. 58±68) and composite MACE rate at 90 days after PCI. The total bleeding rate in the study group was lower than in control group (P<0.05). Rate of thrombocytopenia was similar between groups. CONCLUSION: Among aged AMI patients undergoing primary PCI, results are similar between half-dose and standard dose maintenance administration of tirofiban in terms of inhibition of platelet aggregation, coronary flow, myocardial perfusion, infarct size, left ventricular systolic function and short-term clinical outcomes, but IC bolus plus intravenous half-dose maintenance administration of tirofiban is superior to standard dose injection in lowering bleeding complications rates.

参考文献/References

[1]Jneid H,Anderson JL,Wright RS,et al.American college of cardiology foundation;American heart association task force on practice guidelines.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction(updating the 2007guideline and replacing the 2011 focused update):a report of the American college of cardiology foundation/American heart association task force on practice guidelines[J].Circulation, 2012, 126(7):875-910.
[2]O'gara PT,Kushner FG,ascheim DD,et al.American college of cardiology foundation/American heart association task force on practice guidelines.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American college of cardiology foundation/American heart association task force on practice guidelines[J].Circulation,2013,127(4):e362-e425.
[3]Wu TG,Zhao Q,Huang WG,et al.Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome[J].Circ J,2008,72(10):1605-1609.
[4]替罗非班治疗冠状动脉粥样硬化性心脏病专家共识组. 替罗非班在冠状动脉粥样硬化性心脏病治疗的中国专家共识[J].中华内科杂志,2013,52(5):434-439.
[5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2010,38(8):675-687.
[6]Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)[J].J Am Coll Cardiol,2007,50(7):e1-e157.
[7]中华医学会心血管病学分会,心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2009,37(1):4-25.
[8]Zeymer U,Schr?der K,Wegscheider K,et al.ST resolution in a single electrocardiographic Lead:a simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction[J].Am Heart J,2005,149(1):91-97.
[9]Prati F,Capodanno D,Pawlowski T,et al.Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes[J].JACC Cardiovasc Interv,2010,3(9):928-934.
[10]Gibson CM,Cannon CP,Murphy SA,et al.Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs[J].Circulation,2000,101(2):125-130.
[11]Antman EM,Morrow DA,Mccabe CH,et al.Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction.Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25(ExTRACT-TIMI 25)[J].Am Heart J,2005,149(2):217-226.
[12]Balghith MA.High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - the tamip study[J].Heart Views,2012,13(3):85-90.
[13]Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes[J].Circulation,2006,114(8):774-782.
[14]Burzotta F,Trani C,Romagnoli E,et al.Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty(REMEDIA)trial[J].J Am Coll Cardiol, 2005,46(2):371-376.
[15]Niccoli G,Burzotta F,Galiuto L,et al.Myocardial No-Reflow in humans[J].J Am Coll Cardiol,2009,54(4):281-292.
[16]De Vita M,Coluccia V,Burzotta F,et al.Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions[J].Curr Vasc Pharmacol,2012,10(4):448-453.
[17]Petricevi? M,Biocina B,Konosi? S,et al.Definition of acetylsalicylic acid resistance using whole blood impedance aggregometry in patients undergoing coronary artery surgery[J].Coll Antropol,2013,37(3):833-839.
[18]Petricevic M,Biocina B,Konosic S,et al.Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment May prompt a Switch to dual antiplatelet therapy[J].Heart Vessels,2013,28(1):57-65.
[19]Batchelor WB,Tolleson TR,Huang Y,et al.Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes:the COMPARE trial.Comparison Of Measurements of Platelet aggregation with Aggrastat,Reopro,an[J].Circulation,2002,106(12):1470-1476.
[20]Brown DL.Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment[J].Heart,2003,89(5):535-537.

备注/Memo

备注/Memo:

收稿日期：2014-08-19.
基金项目：广东省科技厅项目资助(2010B080702010)
通讯作者：吴同果，教授，主要从事介入心脏病学研究 Email：wutongguo@sohu.com
作者简介：何芸，主治医师,硕士 Email：qingshuiwu@163.com

常用功能

更新日期/Last Update: 2014-11-18